Rana Hawamdeh, MD
Medical Oncology · Indianapolis, INNPI 1992016588
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 97 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,543 and has fallen 98.5% since, to $24 in 2022. That places this record below the midpoint for medical oncology clinicians in IN, where the typical reported total is $2,472.
Across 97 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$245
- Novartis$158
- Amgen$131
- Daiichi Sankyo Inc.$114
- Incyte Corporation$109
- Seagen Inc.$108
- plus $835 from 23 others
What the payments were for
- Food & beverage$1,699100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 12 | $245 |
| Novartis | 11 | $158 |
| Amgen | 8 | $131 |
| Daiichi Sankyo Inc. | 8 | $114 |
| Incyte Corporation | 5 | $109 |
| Seagen Inc. | 7 | $108 |
| Merck | 6 | $97 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $91 |
| AstraZeneca(2 entities) | 5 | $81 |
| Puma Biotechnology, Inc. | 1 | $79 |
| Sanofi | 4 | $77 |
| Exelixis Inc. | 3 | $50 |
| Eisai Inc. | 3 | $45 |
| Morphosys, US Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $35 |
| Gilead | 2 | $30 |
| Johnson & Johnson | 1 | $24 |
| AbbVie | 1 | $22 |
| Genentech USA, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Deciphera Pharmaceuticals Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Bayer | 1 | $15 |
| Blueprint Medicines Corporation | 1 | $14 |
| Karyopharm Therapeutics Inc. | 1 | $14 |
| Foundation Medicine, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Beigene USA, Inc. | 1 | $12 |
How this compares
$1,699 in reported general payments places this provider in the 40th percentile of 67 medical oncology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 46 | $682,958 |
| ScemblixAsciminib Hydrochloride | 13 | $282,083 |
| RevlimidLenalidomide | 22 | $259,503 |
| ImbruvicaIbrutinib | 15 | $203,539 |
| LynparzaOlaparib | 13 | $203,163 |
| EliquisApixaban | 177 | $191,322 |
| VerzenioAbemaciclib | 12 | $182,102 |
| XareltoRivaroxaban | 46 | $44,829 |
| Exemestane | 70 | $18,833 |
| Anastrozole | 270 | $11,269 |
| LokelmaSodium Zirconium Cyclosilicate | 17 | $10,598 |
| Ondansetron Hcl | 111 | $9,790 |
| Letrozole | 33 | $3,507 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 67 | $1,799 |
| Prochlorperazine Maleate | 88 | $1,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $245 | $874,280223 claims |
| NovartisScemblix | $158 | $282,08313 claims |
| AstraZenecaLynparza, Lokelma | $81 | $213,76130 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $91 | $203,53915 claims |
| Lilly USA, LLCVerzenio | $16 | $182,10212 claims |
| Johnson & JohnsonXarelto | $24 | $44,82946 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 67 medical oncology providers in Indiana.
Other medical oncology in Indianapolis
- Natraj AmmakkanavarIndianapolis$129K
- Bert OneilIndianapolis$89K
- Pablo BedanoIndianapolis$52K
- Gregory SmithIndianapolis$46K
- Ashwin VasudevamurthyIndianapolis$44K
- Daniel SonnenburgIndianapolis$37K
- Sumeet BhatiaIndianapolis$24K
- Michael SlaughterIndianapolis$17K
- Elsayed AlyIndianapolis$9K
- Anuj AgarwalaIndianapolis$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.